International Pancreatic Cancer Scientist Prof. Baiyong Shen Joins Cancer Drug Resistance as Associate Editor

We are thrilled to announce that Prof. Baiyong Shen, a globally recognized leader in pancreatic cancer research and Vice President of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, has officially joined Cancer Drug Resistance as an Associate Editor. His appointment marks a significant milestone for the journal, injecting world-class expertise and reinforcing our commitment to advancing innovation in cancer drug resistance and precision oncology.

Prof. Baiyong Shen is an internationally acclaimed expert in pancreatic diseases, known for his pioneering contributions to both clinical and translational research. He holds numerous prestigious titles, including Foreign Corresponding Member of the French National Academy of Medicine, Fellow of the American College of Surgeons, Deputy Director of the State Key Laboratory of Oncogenes and Related Genes, and Vice President of Ruijin Hospital. In recognition of his outstanding contributions to medicine, he was awarded the Chevalier of the Legion of Honor by the French government.

With over 30 years dedicated to pancreatic cancer research, Prof. Shen has remained steadfast in his mission: to decode the biology of pancreatic cancer and improve patient outcomes. His work spans groundbreaking achievements in basic science, targeted therapies, and clinical application.

Pioneering Precision: Unlocking the Roots of Resistance

Prof. Shen’s team developed a novel molecular subtyping system for pancreatic cancer, unveiling key genetic mutations and mechanisms of metastasis. Their identification of new diagnostic biomarkers has laid a critical foundation for early detection and individualized treatment.

Target Discovery: Transforming Treatment Paradigms

• Prof. Shen's group was the first to discover the potential of bee venom in pancreatic cancer therapy, opening an exciting new frontier in natural compound research.
• They established China’s largest pancreatic ductal adenocarcinoma PDX model library (over 30 models), using multi-omics approaches to identify five novel targeted drugs. Notably, their PGAM1 inhibitor significantly enhanced chemotherapy efficacy by targeting glycolysis, a breakthrough published in Proceedings of the National Academy of Sciences (PNAS).
• The team also revealed key immune suppression mechanisms within the tumor microenvironment, identifying novel targets that improve immune responses—offering new strategies to overcome immunotherapy resistance.

From Bench to Bedside: Shaping Global Guidelines

In 2024, Prof. Shen’s team published a landmark cover study in Nature Medicine, reporting the world’s first protein biomarker capable of predicting chemotherapy sensitivity in pancreatic cancer. This discovery directly advanced treatment optimization and has been hailed as a potential catalyst for updating international clinical guidelines to improve survival outcomes.

Drug resistance remains one of the greatest challenges in precision cancer therapy. As a leading platform in this field, Cancer Drug Resistance is dedicated to facilitating high-level academic exchange and promoting transformative research. Prof. Shen’s appointment as Associate Editor is poised to bring invaluable insights and drive the journal to new heights.

We are confident that under Prof. Shen’s leadership, Cancer Drug Resistance will continue to foster interdisciplinary collaboration, accelerate translational breakthroughs, and bring new hope to cancer patients worldwide.

Editor: Louise Pan
Language Editor: Catherine Yang
Production Editor: Ting Xu
Respectfully Submitted by the Editorial Office of Cancer Drug Resistance